ADC Therapeutics SA, a commercial-stage biotechnology company founded in 2011 and headquartered in Epalinges, Switzerland, is focused on developing antibody drug conjugates (ADCs) to treat patients with hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is currently undergoing various clinical trials, including a Phase II trial for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, a Phase III trial in combination with rituximab for relapsed or refractory DLBCL in second-line transplant-ineligible patients, and a Phase I trial targeting relapsed or refractory non-Hodgkin lymphoma (NHL). In addition, the company is actively developing camidanlumab tesirine, which has completed its Phase I trial for relapsed or refractory NHL, is in Phase II for relapsed or refractory Hodgkin lymphoma, and is undergoing a Phase Ib trial for selected advanced solid tumors. The company's commitment to innovation is further demonstrated through the development of ADCT-602, currently in a Phase Ia trial for acute lymphoblastic leukemia, as well as ADCT-601 and ADCT-901, both also in Phase Ia trials targeting various solid tumors. The company's financial health is reflected in its reported depreciation and amortization expenses of $3,276,000.00 which indicate the ongoing wear and tear of its assets. The gross profit ratio stands at 0.91 showcasing the efficiency of its production and sales operations, while a revenue of $69,280,000.00 highlights its focused approach in a niche market. However, the company also reported selling, general, and administrative expenses of $85,909,000.00 pointing to its operational overheads, and has earned an interest income of $12,272,000.00 further reflecting the scope of its financial investments. Furthermore, ADC Therapeutics holds a significant position in the biotechnology sector, classified as a small-cap player with a market capitalization of $349,871,890.00. The company's stock is affordable at $3.35 making it particularly suitable for budget-conscious investors. With an average trading volume of 823,232.00 the stock denotes moderate liquidity, allowing for easier transactions in the market. Being a key player in the biotechnology industry, ADC Therapeutics contributes substantially to the overall market landscape, thereby driving innovation and growth within its sector. Through collaborative efforts with partners such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited, the company aims to enhance its research and development capabilities, ultimately delivering impactful therapies to patients in need.